Penn Pharma and Xcelience, LLC have entered into a joint venture agreement to provide Capsugel’s Xcelodose precision powder micro-dosing system technology on a global basis. Xcelodose is a registered trademark of Capsugel, a division of Pfizer. The JV aims to provide pharma and biopharma companies with the opportunity to manufacture first in human batches faster and closer to clinical sites. The companies will operate on the network of Xcelodose systems worldwide, which is designed to guaran...